

3-Methylthienyl-carbonyl-JNJ-7706621 Biochemical

3-Methylthienyl-carbonyl-JNJ-7706621

CATALOG #
AAA228717


PRODUCT SYNONYMS

3-Methylthienyl-carbonyl-JNJ-7706621; 3-Methylthienyl-carbonyl-JNJ-7706621 biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	443798-09-2
Targets&IC50	CDK4:0.11 uM (IC50), GSK3:41 nM (IC50), CDK2/CyclinA:2 nM (IC50), FGFR2:0.22 uM (IC50), CDK1/CyclinB:6.4 nM (IC50), VEGFR2:0.13 uM (IC50)
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	3-Methylthienyl-carbonyl-JNJ-7706621 (75-125 mg/kg; i.p. once daily for 32 days) inhibits the A375 human melanoma tumor growth and prolongs the survival in nude mice[1]. 3-Methylthienyl-carbonyl-JNJ-7706621 exhibits oral bioavailability (nude mouse 2%, rat 8%, dog 63.3%), terminal elimination half-lives (nude mouse 1.70, rat 2.20 and, dog 2.36 h) and C max (nude mouse 0.21, rat 2.5, dog 4.58 uM) following oral administration (nude mouse 30, rat 30, dog 10 mg/kg)[1]. 3-Methylthienyl-carbonyl-JNJ-7706621 exhibits terminal elimination half-lives (nude mouse 0.51, rat 0.64 and, dog 3.89 h), C max (nude mouse 6.4, rat 23.2, dog 2.19 uM) and AUC (nude mouse 3.2, rat 11.4, dog 2.45 uM/h) following intravenous administration (nude mouse 3, rat 3 and, dog 1 mg/kg)[1]. Animal Model: Male athymic mice were implanted with A375 human melanoma cells[1]. Dosage: 75, 100, 125 mg/kg. Administration: I.p. once daily for 32 days. Result: Reduced the tumor growth. Survival was increased by about 3 weeks compared with vector alone.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
Biotin-PEG1-NH2, CAS 811442-85-0



Structure
Biotin-PEG1-NH2, CAS 811442-85-0

ADDITIONAL INFORMATION

Related Product Information for 3-Methylthienyl-carbonyl-JNJ-7706621 biochemical	3-Methylthienyl-carbonyl-JNJ-7706621 is a potent and selective inhibitor of cyclin-dependent kinase (CDK), with IC 50 s of 6.4 nM and 2 nM for CDK1/cyclin B and CDK2/cyclin A, respectively. 3-Methylthienyl-carbonyl-JNJ-7706621 also shows potent inhibition of GSK-3 (IC 50 =0.041 uM) and modest potency against CDK4, VEGF-R2, and FGF-R2 (IC 50 =0.11, 0.13, 0.22 uM, respectively). 3-Methylthienyl-carbonyl-JNJ-7706621 can be used for the research of cancer.
References	1. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.

AAA Biotech | Tel: +1 (619) 604-9440 | Fax: +1 (619) 604-9441 | contact@aaabiotech.com

Online datasheet: <https://stage.aaabiotech.com/biochemical/3-methylthienyl-carbonyl-jnj-7706621/228717>